// App-Quantinova.ai

724 : First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Niels W.C.J. Van De Donk

Principal Investigators

  • Jeremy Larsen

  • Monique C. Minnema

  • Sundar Jagannath

  • Albert Oriol

  • Jeffrey Zonder

  • Paul G. Richardson

  • Paula Rodriguez-Otero

  • Ashraf Z. Badros

  • Edward Stadtmauer

  • Sara Bringhen

  • Erica Campagnaro

  • David S. Siegel

  • Barbara Gamberi

  • Mercedes Gironella Mesa

  • Pieter Sonneveld

  • Tuong Vi Nguyen

  • Antonia Di Micco

  • April Sorrell

  • Min Chen

  • Michael Amatangelo

  • Elisabeth Kueenburg

  • Sagar Lonial

Medical Centers

  • Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, Netherlands

  • NIHR Clinical Research Facility, University College London Hospitals, London, United Kingdom

  • Mayo Clinic, Scottsdale, AZ

  • Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

  • Mount Sinai Hospital, New York, NY

  • Institut Josep Carreras and Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain

  • Karmanos Cancer Institute, Detroit, MI

  • Dana-Farber Cancer Institute, Boston, MA

  • Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain

  • The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD

  • University of Pennsylvania, Philadelphia, PA

  • Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Torino, Italy

  • Michigan Medicine Hematology Clinic, University of Michigan Rogel Cancer Center, Ann Arbor, MI

  • Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

  • Hematology Unit, AUSL-IRCSS, Reggio Emilia, Italy

  • University Hospital Vall d'Hebron, Barcelona, Spain

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Winship Cancer Institute of Emory University, Atlanta, GA

Locations

  • Netherlands

  • United Kingdom

  • United States

  • Spain

  • Italy

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • daratumumab Intravenous

  • Bortezomib

  • CC-220

  • Sparsentan

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I/II

Study Id's

  • NCT02773030

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved